Innovent inks agreement with Roche for Novel DLL3 ADC
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
The celebrations began with the unveiling of the Biocon Anthem
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
The newly setup entity, Emcutix Biopharmaceuticals Limited, plans to significantly expand Emcure’s offerings
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
We now rank 3rd in pharmaceutical production by volume and 14th by value
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
Subscribe To Our Newsletter & Stay Updated